GO
Loading...

Biogen Idec Inc

More

  • Midday Glance: Biotechnology companies Thursday, 21 Aug 2014 | 1:22 PM ET

    Amgen Inc. rose$. 03 or percent, to $132.71. Biogen Idec fell $2.14 or. 6 percent, to $340.45. Celgene Corp. rose$. 02 or percent, to $92.02.

  • Aug 21- Baxter International Inc said a more potent version of its flagship blood disorder drug Advate met the main goal in a late-stage study.

  • Final Glance: Biotechnology companies Wednesday, 20 Aug 2014 | 6:02 PM ET

    Amgen Inc. fell$. 34 or. 3 percent, to $132.68. Biogen Idec fell $3.26 or. 9 percent, to $342.58. Celgene Corp. rose$. 64 or. 7 percent, to $92.00.

  • Midday Glance: Biotechnology companies Wednesday, 20 Aug 2014 | 1:49 PM ET

    Amgen Inc. fell$. 35 or. 3 percent, to $132.67. Biogen Idec fell $2.66 or. 8 percent, to $343.18. Celgene Corp. rose $1.38 or 1.5 percent, to $92.74.

  • Early Glance: Biotechnology companies Wednesday, 20 Aug 2014 | 12:21 PM ET

    Amgen Inc. fell$. 61 or. 5 percent, to $132.41. Biogen Idec fell $1.68 or. 5 percent, to $344.16. Celgene Corp. rose $1.47 or 1.6 percent, to $92.83.

  • Final Glance: Biotechnology companies Tuesday, 19 Aug 2014 | 6:08 PM ET

    Amgen Inc. fell$. 20 or. 2 percent, to $133.02. Biogen Idec rose $1.24 or. 4 percent, to $345.84. Celgene Corp. rose$. 05 or. 1 percent, to $91.36.

  • Midday Glance: Biotechnology companies Tuesday, 19 Aug 2014 | 4:03 PM ET

    Amgen Inc. fell $1.29 or 1.0 percent, to $131.93. Biogen Idec fell$. 31 or. 1 percent, to $344.29. Celgene Corp. rose$. 10 or. 1 percent, to $91.41.

  • Final Glance: Biotechnology companies Monday, 18 Aug 2014 | 6:02 PM ET

    Amgen Inc. rose$. 42 or. 3 percent, to $133.22. Biogen Idec rose $2.13 or. 6 percent, to $344.60. Celgene Corp. rose $1.71 or 1.9 percent, to $91.31.

  • Early Glance: Biotechnology companies Monday, 18 Aug 2014 | 10:29 AM ET

    Amgen Inc. rose $1.09 or. 8 percent, to $133.89. Biogen Idec rose $3.18 or. 9 percent, to $345.65. Celgene Corp. rose $1.70 or 1.9 percent, to $91.30.

  • FDA approves Biogen's MS drug Plegridy Friday, 15 Aug 2014 | 7:27 PM ET

    CAMBRIDGE, Mass.— Biogen Idec says that federal regulators have approved the specialty drugmaker's new treatment for people with relapsing forms of multiple sclerosis.

  • Final Glance: Biotechnology companies Friday, 15 Aug 2014 | 6:16 PM ET

    Amgen Inc. rose$. 94 or. 7 percent, to $132.80. Biogen Idec rose $5.46 or 1.6 percent, to $342.47. Celgene Corp. rose $1.15 or 1.3 percent, to $89.61.

  • Midday Glance: Biotechnology companies Friday, 15 Aug 2014 | 1:15 PM ET

    Amgen Inc. fell$. 50 or. 4 percent, to $131.36. Biogen Idec rose$. 93 or. 3 percent, to $337.94. Celgene Corp. rose$. 77 or. 9 percent, to $89.23.

  • Early Glance: Biotechnology companies Friday, 15 Aug 2014 | 11:21 AM ET

    Amgen Inc. fell$. 65 or. 5 percent, to $131.21. Biogen Idec rose $1.59 or. 5 percent, to $338.60. Celgene Corp. rose $1.25 or 1.4 percent, to $89.71.

  • Final Glance: Biotechnology companies Wednesday, 13 Aug 2014 | 6:14 PM ET

    Amgen Inc. rose $1.02 or. 8 percent, to $127.34. Biogen Idec rose $9.68 or 3.0 percent, to $334.64. Celgene Corp. rose $1.97 or 2.3 percent, to $88.41.

  • Cramer: Why the Street is preparing for the worst Wednesday, 13 Aug 2014 | 6:08 PM ET

    Cramer often look inside the market for insights on broad sentiment. And certain things happened on Wednesday that suggest trouble.

  • Traders work on the floor of the New York Stock Exchange, Aug. 1, 2014, in New York.

    U.S. stocks closed higher for the third time in four days as a rally in tech, airlines and biotech firms helped lead gains.

  • US STOCKS-Wall Street rises, biotech shares lead rally Wednesday, 13 Aug 2014 | 2:56 PM ET

    NEW YORK, Aug 13- U.S. stocks rose on Wednesday, with the Dow returning to positive territory for the year as the market shrugged off weak earnings reports and a slump in retail shares. Biotech shares surged, with the Nasdaq biotech index climbing 2.1 percent on the back of stocks including InterMune Inc and Jazz Pharmaceuticals PLC.

  • Midday Glance: Biotechnology companies Wednesday, 13 Aug 2014 | 1:50 PM ET

    Amgen Inc. rose$. 83 or. 7 percent, to $127.15. Biogen Idec rose $8.44 or 2.6 percent, to $333.40. Celgene Corp. rose $1.70 or 2.0 percent, to $88.14.

  • Biogen, Twitter—and CNBC—take ice bucket challenge Wednesday, 13 Aug 2014 | 12:29 PM ET
    Scott Wapner gets iced after accepting the Ice Bucket Challenge!

    Propelled by Facebook and Twitter, the ice bucket challenge has become a viral sensation. Now Biogen executives and CNBC are rising to the challenge.

  • Early Glance: Biotechnology companies Wednesday, 13 Aug 2014 | 10:31 AM ET

    Amgen Inc. rose$. 15 or. 1 percent, to $126.47. Biogen Idec rose $3.01 or. 9 percent, to $327.97. Celgene Corp. rose$. 22 or. 2 percent, to $86.66.